Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk
Delahanty RJ, Xiang YB, Spurdle A, Beeghly-Fadiel A, Long J, Thompson D, Tomlinson I, Yu H, Lambrechts D, Dörk T, Goodman MT, Zheng Y, Salvesen HB, Bao PP, Amant F, Beckmann MW, Coenegrachts L, Coosemans A, Dubrowinskaja N, Dunning A, Runnebaum IB, Easton D, Ekici AB, Fasching PA, Halle MK, Hein A, Howarth K, Gorman M, Kaydarova D, Krakstad C, Lose F, Lu L, Lurie G, O'Mara T, Matsuno RK, Pharoah P, Risch H, Corssen M, Trovik J, Turmanov N, Wen W, Lu W, Cai Q, Zheng W, Shu XO. Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2013, 22: 216-223. PMID: 23221126, PMCID: PMC3677562, DOI: 10.1158/1055-9965.epi-12-0903.Peer-Reviewed Original ResearchMeSH KeywordsAsian PeopleBiomarkers, TumorCase-Control StudiesChinaEndometrial NeoplasmsFemaleFollow-Up StudiesGene Expression ProfilingGenetic Predisposition to DiseaseHumansInflammationLinkage DisequilibriumMiddle AgedNeoplasm StagingOligonucleotide Array Sequence AnalysisPolymorphism, Single NucleotidePrognosisRisk FactorsConceptsEndometrial cancer riskEndometrial cancer casesEndometrial cancerSingle nucleotide polymorphismsOdds ratioCancer casesEndometrial carcinogenesisCancer riskStage IConfidence intervalsInflammation pathway genesInflammatory pathway genesAllelic odds ratioChronic inflammationEpidemiologic evidenceInflammatory pathwaysPathway genesSignificant associationStage IIGenetic susceptibilityMMP9 polymorphismsAdditional studiesCancerGenetic polymorphismsFollow-up genotyping